Erratum: Expression of Concern: Blockade of Fas signaling in breast cancer cells suppresses tumor growth and metastasis via disruption of Fas signaling-initiated cancer-related inflammation (Journal of Biological Chemistry (2014) 289 (11522-11535) DOI: 10.1074/jbc.M113.525014);Blockade of fas signaling in breast cancer cells suppresses tumor growth and metastasis via disruption of fas signaling-initiated cancer-related inflammation

Journal of Biological Chemistry

Volumn 289, Issue 16, 2014, Pages 11522-11535

  Liu, Qiuyan ^a   Tan, Qinchun ^b   Zheng, Yuanyuan ^a   Chen, Kun ^b   Qian, Cheng ^a   Li, Nan ^a   Wang, Qingqing ^b   Cao, Xuetao ^a,b,c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; DISEASES; PATHOLOGY; SIGNALING; TUMORS;

APOPTOTIC FUNCTION; BREAST CANCER CELLS; POTENTIAL TARGETS; TUMOR GROWTH; TUMOR PROGRESSIONS;

CELL SIGNALING;

FAS ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38; PROSTAGLANDIN E2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN TISSUE; IN VIVO STUDY; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; METASTASIS INHIBITION; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; TUMOR XENOGRAFT;

BREAST CANCER; FAS; IL-6; INFLAMMATION; MDSC; PGE2; PROSTAGLANDINS; TUMOR METASTASES;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, CD95; BREAST NEOPLASMS; CELL LINE, TUMOR; DINOPROSTONE; FEMALE; HETEROGRAFTS; HUMANS; INFLAMMATION; INTERLEUKIN-6; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 84898965762     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.EC120.014573     Document Type: Erratum

References (50)

1. Restifo, N. P. (2000) Not so Fas. Re-evaluating the mechanisms of immune privilege and tumor escape. Nat. Med. 6, 493-495
2. Peter, M. E., Budd, R. C., Desbarats, J., Hedrick, S. M., Hueber, A. O., Newell, M. K., Owen, L. B., Pope, R. M., Tschopp, J., Wajant, H., Wallach, D., Wiltrout, R. H., Zörnig, M., and Lynch, D. H. (2007) The CD95 receptor. Apoptosis revisited. Cell 129, 447-450
3. Wajant, H., Pfizenmaier, K., and Scheurich, P. (2003) Non-apoptotic Fas signaling. Cytokine Growth Factor Rev. 14, 53-66
4. Rothstein, T. L. (2000) Inducible resistance to Fas-mediated apoptosis in B cells. Cell Res. 10, 245-266
5. Chen, L., Park, S. M., Tumanov, A. V., Hau, A., Sawada, K., Feig, C., Turner, J. R., Fu, Y. X., Romero, I. L., Lengyel, E., and Peter, M. E. (2010) CD95 promotes tumour growth. Nature 465, 492-496
6. Peter, M. E., Legembre, P., and Barnhart, B. C. (2005) Does CD95 have tumor promoting activities? Biochim. Biophys. Acta 1755, 25-36
7. Mitsiades, C. S., Poulaki, V., Fanourakis, G., Sozopoulos, E., McMillin, D., Wen, Z., Voutsinas, G., Tseleni-Balafouta, S., and Mitsiades, N. (2006) Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation. Clin. Cancer Res. 12, 3705-3712
8. Hoogwater, F. J., Steller, E. J., Westendorp, B. F., Borel Rinkes, I. H., and Kranenburg, O. (2012) CD95 signaling in colorectal cancer. Biochim. Biophys. Acta 1826, 189-198
9. Zheng, H. X., Cai, Y. D., Wang, Y. D., Cui, X. B., Xie, T. T., Li, W. J., Peng, L., Zhang, Y., Wang, Z. Q., Wang, J., and Jiang, B. (2013) Fas signaling promotes motility and metastasis through epithelial-mesenchymal transition in gastrointestinal cancer. Oncogene 32, 1183-1192
10. Nijkamp, M. W., Hoogwater, F. J., Steller, E. J., Westendorp, B. F., van der Meulen, T. A., Leenders, M. W., Borel Rinkes, I. H., and Kranenburg, O. (2010) CD95 is a key mediator of invasion and accelerated outgrowth of mouse colorectal liver metastases following radiofrequency ablation. J. Hepatol. 53, 1069-1077
11. Kleber, S., Sancho-Martinez, I., Wiestler, B., Beisel, A., Gieffers, C., Hill, O., Thiemann, M., Mueller, W., Sykora, J., Kuhn, A., Schreglmann, N., Letellier, E., Zuliani, C., Klussmann, S., Teodorczyk, M., Gröne, H. J., Ganten, T. M., Sültmann, H., Tüttenberg, J., von Deimling, A., Regnier- Vigouroux, A., Herold-Mende, C., and Martin-Villalba, A. (2008) Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 13, 235-248
12. Steller, E. J., Borel Rinkes, I. H., and Kranenburg, O. (2011) How CD95 stimulates invasion. Cell Cycle 10, 3857-3862
13. Steller, E. J., Ritsma, L., Raats, D. A., Hoogwater, F. J., Emmink, B. L., Govaert, K. M., Laoukili, J., Rinkes, I. H., van Rheenen, J., and Kranenburg, O. (2011) The death receptor CD95 activates the cofilin pathway to stimulate tumour cell invasion. EMBO Rep. 12, 931-937
14. Wisniewski, P., Ellert-Miklaszewska, A., Kwiatkowska, A., and Kaminska, B. (2010) Non-apoptotic Fas signaling regulates invasiveness of glioma cells and modulates MMP-2 activity via NFκB-TIMP-2 pathway. Cell. Signal. 22, 212-220
15. Farley, S. M., Purdy, D. E., Ryabinina, O. P., Schneider, P., Magun, B. E., and Iordanov, M. S. (2008) Fas ligand-induced proinflammatory transcriptional responses in reconstructed human epidermis. Recruitment of the epidermal growth factor receptor and activation of MAP kinases. J. Biol. Chem. 283, 919-928
16. Imamura, R., Konaka, K., Matsumoto, N., Hasegawa, M., Fukui, M., Mukaida, N., Kinoshita, T., and Suda T. (2004) Fas ligand induces cell-autonomous NF-κB activation and interleukin-8 production by a mechanism distinct from that of tumor necrosis factor-α. J. Biol. Chem. 279, 46415-46423
17. Farley, S. M., Dotson, A. D., Purdy, D. E., Sundholm, A. J., Schneider, P., Magun, B. E., and Iordanov M. S. (2006) Fas ligand elicits a caspase-independent proinflammatory response in human keratinocytes. Implications for dermatitis. J. Invest. Dermatol. 126, 2438-2451
18. Qian, C., Qian, L., Yu, Y., An, H., Guo, Z., Han, Y., Chen, Y., Bai, Y., Wang, Q., and Cao, X. (2013) Fas signal promotes the immunosuppressive function of regulatory dendritic cells via ERK/β-catenin pathway. J. Biol. Chem. 288, 27825-27835
19. Letellier, E., Kumar, S., Sancho-Martinez, I., Krauth, S., Funke-Kaiser, A., Laudenklos, S., Konecki, K., Klussmann, S., Corsini, N. S., Kleber, S., Drost, N., Neumann, A., Lévi-Strauss, M., Brors, B., Gretz, N., Edler, L., Fischer, C., Hill, O., Thiemann, M., Biglari, B., Karray, S., and Martin-Villalba, A. (2010) CD95-ligand on peripheral myeloid cells activates Syk kinase to trigger their recruitment to the inflammatory site. Immunity 32, 240-252
20. Zhang, Y., Liu, Q., Zhang, M., Yu, Y., Liu, X., and Cao, X. (2009) Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2. J. Immunol. 182, 3801-3808
21. Cai, Z., Yang, F., Yu, L., Yu, Z., Jiang, L., Wang, Q., Yang, Y., Wang, L., Cao, X., and Wang, J. (2012) Activated T cell exosomes promote tumor invasion via Fas signaling pathway. J. Immunol. 188, 5954-5961
22. Guo, Z., Zhang, M., An, H., Chen, W., Liu, S., Guo, J., Yu, Y., and Cao, X. (2003) Fas ligation induces IL-1β-dependent maturation and IL-1β-independent survival of dendritic cells. Different roles of ERK and NF-κB signaling pathways. Blood 102, 4441-4447
23. Guo, Z., Zhang, M., Tang, H., and Cao, X. (2005) Fas signal links innate and adaptive immunity by promoting dendritic cell secretion of CC and CXC chemokines. Blood 106, 2033-2041
24. Chen, T., Guo, J., Han, C., Yang, M., and Cao, X. (2009) Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway. J. Immunol. 182, 1449-1459
25. Chen, T., Guo, J., Yang, M., Zhu, X., and Cao X. (2011) Chemokinecontaining exosomes are released from heat-stressed tumor cells via lipid raft-dependent pathway and act as efficient tumor vaccine. J. Immunol. 186, 2219-2228
26. Zhang, Y., Lv, D., Kim, H. J., Kurt, R. A., Bu, W., Li, Y., and Ma, X. (2013) A novel role of hematopoietic CCL5 in promoting triple-negative mammary tumor progression by regulating generation of myeloid-derived suppressor cells. Cell Res. 23, 394-408
27. Villa-Morales, M., and Fernández-Piqueras, J. (2012) Targeting the Fas/ FasL signaling pathway in cancer therapy. Expert. Opin. Ther. Targets 16, 85-101
28. Mantovani, A., Allavena, P., Sica, A., and Balkwill, F. (2008) Cancer-related inflammation. Nature 454, 436-444
29. Hanahan, D., and Weinberg, R. (2011) Hallmarks of cancer. The next generation. Cell 144, 646-674
30. Hanahan, D., and Coussens, L. M. (2012) Accessories to the crime. Functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309-322
31. Peranzoni, E., Zilio, S., Marigo, I., Dolcetti, L., Zanovello, P., Mandruzzato, S., and Bronte V. (2010) Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol. 22, 238-244
32. Meyer, C., Sevko, A., Ramacher, M., Bazhin, A. V., Falk, C. S., Osen, W., Borrello, I., Kato, M., Schadendorf, D., Baniyash, M., and Umansky, V. (2011) Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc. Natl. Acad. Sci. U.S.A. 108, 17111-17116
33. Ostrand-Rosenberg, S., and Sinha, P. (2009) Myeloid-derived suppressor cells. Linking inflammation and cancer. J. Immunol. 182, 4499-4506
34. Li, H., Han, Y., Guo, Q., Zhang, M., and Cao, X. (2009) Cancer-expanded myeloid-derived suppressor cells induce anergy ofNKcells through membrane- bound transforming growth factor-β1. J. Immunol. 182, 240-249
35. Yang, L., DeBusk, L. M., Fukuda, K., Fingleton, B., Green-Jarvis, B., Shyr, Y., Matrisian, L. M., Carbone, D. P., and Lin, P. C. (2004) Expansion of myeloid immune suppressor Gr1+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6, 409-421
36. Diaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E., Cole, D. J., and Montero, A. J. (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer. Stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 58, 49-59
37. Han, Y., Guo, Q., Zhang, M., Chen, Z., and Cao, X. (2009) CD69+CD4+CD25 T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-β1. J. Immunol. 182, 111-120
38. Hou, J., Lin, L., Zhou, W., Wang, Z., Ding, G., Dong, Q., Qin, L., Wu, X., Zheng, Y., Yang, Y., Tian, W., Zhang, Q., Wang, C., Zhang, Q., Zhuang, S. M., Zheng, L., Liang, A., Tao, W., and Cao, X. (2011) Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR- 199a/b-3p as a therapeutic target for hepatocellular carcinoma. Cancer Cell 19, 232-243
39. Steiner, G. E., Ecker, R. C., Kramer, G., Stockenhuber, F., and Marberger, M. J. (2000) Automated data acquisition by confocal laser scanning microscopy and image analysis of triple stained immunofluorescent leukocytes in tissue. J. Immunol. Methods 237, 39-50
40. Liu, Q., Chen, T., Chen, G., Shu, X., Sun, A., Ma, P., Lu, L., and Cao, X. (2007) Triptolide impairs dendritic cell migration by inhibiting CCR7 and COX-2 expression through PI3-K/Akt and NF-κB pathways. Mol. Immunol. 44, 2686-2696
41. Keane, M. M., Ettenberg, S. A., Lowrey, G. A., Russell, E. K., and Lipkowitz, S. (1996) Fas expression and function in normal and malignant breast cell lines. Cancer Res. 56, 4791-4798
42. Lacotte, S., Brun, S., Muller, S., and Dumortier, H. (2009) CXCR3, inflammation, and autoimmune diseases. Ann. N.Y. Acad. Sci. 1173, 310-317
43. Desbarats, J., and Newell, M. K. (2000) Fas engagement accelerates liver regeneration after partial hepatectomy. Nat. Med. 6, 920-923
44. Desbarats, J., Birge, R. B., Mimouni-Rongy, M., Weinstein, D. E., Palerme, J. S., and Newell, M. K. (2003) Fas engagement induces neurite growth through ERK activation and p35 upregulation. Nat. Cell Biol. 5, 118-125
45. Macher-Goeppinger, S., Bermejo, J. L., Wagener, N., Hohenfellner, M., Haferkamp, A., Schirmacher, P., and Roth, W. (2011) Expression and prognostic relevance of the death receptor CD95 (Fas/APO1) in renal cell carcinomas. Cancer Lett. 301, 203-211
46. Ostrand-Rosenberg, S., Sinha, P., Beury, D. W., and Clements, V. K. (2012) Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin. Cancer Biol. 22, 275-281
47. Sinha, P., Clements, V. K., Fulton, A. M., and Ostrand-Rosenberg, S. (2007) Prostaglandin E2 promotes tumor progression by inducing myeloid- derived suppressor cells. Cancer Res. 67, 4507-4513
48. Bunt, S. K., Yang, L., Sinha, P., Clements, V. K., Leips, J., and Ostrand- Rosenberg, S. (2007) Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 67, 10019-10026
49. Montero, A. J., Diaz-Montero, C. M., Kyriakopoulos, C. E., Bronte, V., and Mandruzzato, S. (2012) Myeloid-derived suppressor cells in cancer patients. A clinical perspective. J. Immunother. 35, 107-115
50. Barnhart, B. C., Legembre, P., Pietras, E., Bubici, C., Franzoso, G., and Peter, M. E. (2004) CD95 ligand induces motility and invasiveness of apoptosis- resistant tumor cells. EMBO J. 23, 3175-3185